Profound Medical’s Q2 earnings reveal strong momentum despite a shipment delay: revenue hit $2.5M, up 12% YoY, with $1.6M from recurring revenue and solid 70%+ gross margins. A $3.1M product delay pushed Q2 figures below what could have been a 153% YoY surge. Clinically, the CAPTAIN trial shows TULSA excels in preserving quality of life—and even penile length—outperforming robotic surgery, boosting insurance coverage potential. With a $70M sales pipeline and expanding Medicare reimbursement, Profound is on track for profitable, scalable growth.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
